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Persons aged 18-75 years
European
American
African
American
Other
US Census data 2007-2010,
8 counties of WNY
90% 9.5% <1%
NYS DOH Cancer Registry,
2005-2010 cases of acute
and chronic leukemia,
lymphoma and myeloma in
8 counties of WNY
91% 8% <1%
Total Referrals to BMT program
at RPCI 2005-2011
90.5% 7% 2.5%
Total Referrals to BMT program
at RPCI 2005-2011, and resided
in 1 of 8 counties in WNY
90% 8% 2%
All patients who received a BMT
at RPCI 2005-2011
92% 6% 2%
Received a BMT at RPCI, 2005-2011
and resided in 1 of 8 counties
in WNY
91% 7% 2%
Proportion of BMT referrals who
participated in biospecimen
research, 2005-2011
95% 95% 88%
Proportion of BMT referrals who
participated in survey research,
2005-2011
70% 37% 67%
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Data. From 2005-2011, 1106 patients aged 18-75 years were
referred to our center for BMT consultation, the majority of
whom (74%) reside in the 8 counties of Western NY (WNY).
The Table compares the race of BMT patients, referrals,
cancer cases and general population estimates. Reasons for
not receiving a BMT differed by race with European Ameri-
cans (EAs) mostly due to patient decision (20%) and African
Americans (AAs) mostly due to death before BMT (16%). We
further examined patient characteristics which might inﬂu-
ence referral for BMT consultation and utilization of BMT by
conducting a retrospective cohort study of the 1106 BMT
referrals who participated in our Databank and Bio-Re-
pository (DBBR) biologic specimen banking (one-time blood
sample collection) and epidemiologic questionnaire (written
at 9th grade level, 45 minutes to complete). As shown in the
Table, participation in biospecimen research did not vary by
race, however AAs were signiﬁcantly less likely to participate
in survey research than EAs and other races. While the mi-
nority rates of referrals and BMTmay appear low, they reﬂect
the race distribution of the cancer cases and general popu-
lation in WNY. AAs are equally likely to participate in bio-
specimen banking, but further study is needed to elucidate
reasons for lower participation in survey research.139
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Themaximum tolerated dose (MTD) of lomustine when used
in combinationwith etoposide, ara-C, andmelphalan (LEAM)in a conditioning regimen prior to autologous hematopoietic
stem cell transplantation (HSCT) for lymphoma is unknown.
We performed a phase 1 clinical trial with traditional 3+3
design to determine the MTD of lomustine administered on
D-4 followed by etoposide (1 g/m2 D-3), ara-C (4g/m2 D-2),
and melphalan (140 mg/m2 D -1). Dose-limiting toxicity
(DLT) was deﬁned as grade 3 or 4 non-hematologic or in-
fectious toxicity, delayed engraftment beyond D+30 or death
from any cause. The initial dose of lomustinewas 200mg/m2
(L200 cohort), increased by 200 mg/m2 at each subsequent
cohort (L400, etc). Because L400 exceeded MTD, a third
cohort was created with 300 mg/m2 of lomustine (L300).
Fourteen subjectes entered the trial being 9 with Hodgkin
lymphoma, 2 with mantle cell lymphoma, 1 with diffuse
large B-cell lymphoma, 1 with follicular lymphoma and 1
with peripheral T-cell lymphoma. Subjects were either in PR
(n¼6) or CR (n¼8) after the most recent salvage theapy.
Median age of subjects was 36 years. Six patients were
treated with L200 (1 DLT, death by sepsis), two patients were
treated with L400 (2 DLT, grade 4 gastrointestinal toxicity)
and 6 patients were treated at an intermediate dose of 300
mg/m2 (L300, 1 DLT, neurological grade 4, reversible) and
L300 was declared the MTD. A median number of 6.91 CD34
cells/kg (range 1.37-18.8) were infused. The average duration
of neutropenia (neutrophils <500/mm3) was 7.8 days, lower
than the historical control of 13 days with cyclophospha-
mide, BCNU, and etoposide (CBV) conditioning. Neutrophils
and platelet engraftment occurred on average at day 10 and
12 respectively. We concluded that 300mg/m2 is the MTD of
lomustine in combination with etoposide, ara-C and
melphalan (LEAM) conditioning in autologous-HSCT in pa-
tients with lymphoma. More detailed toxicity proﬁle and
anti-lymphoma activity will be obtained from ongoing
expansion of the L300 cohort. LEAM is a simple conditioning
regimen with rapid dosing, consequent short period of
neutropenia and acceptable toxicity.140
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Background: Plerixafor (Mozobil) plus G-CSF is an FDA-
approved strategy to mobilize hematopoietic stem cells
(HSCs) in patients (pts) with NHL and Multiple Myeloma. We
report our institutional experiencemobilizing HSCs with and
without plerixafor in pts with NHL and HL.
Methods: We collected data on all NHL (n¼85) and HL
(n¼44) pts who underwent mobilization without chemo-
therapy between 2010 and 2012 at Ohio State University
under IRB approved protocols. Our standard is plerixafor on
day 4 of G-CSF in pts who received radiation, 10 cycles of
chemotherapy, are age 60, or on day 5 to pts who had a
CD34 count of <10/mL that morning. Our target CD34+ cell
yield is >5x106 /kg recipient weight, with a minimum of
>2x106 /kg. Factors associated with sufﬁcient mobilization
were evaluated using univariate logistic regressionmodels as
well as graphical analyses.
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median Karnofsky (KPS) score prior to transplant was 90
(range: 70-100); those who received plerixafor (n¼88) ten-
ded to have lower KPS vs. G-CSF alone (n¼41; p¼.07). Median
age of the cohort was 54 years (range: 19-76), with HL pts
younger than NHL pts (median: 37 vs. 60 years). Ability to
collect >2x106 /kg CD34+ cells on day 1 was highly associ-
ated with achieving a total yield of >5x106 /kg CD34+ cells
(OR¼41.6; p<.001). Both collection goals were signiﬁcantly
associated with earlier time to ANC engraftment (p<.001). In
the 88 pts who received plerixafor (75 NHL pts), the median
number of doses was 2 (range: 1-3); 76% received their ﬁrst
dose on day 4 (range: 4-7). Patients who received day 4
plerixafor had signiﬁcantly lower CD34 counts on day 4 than
those that received G-CSF alone (p<.001). Plerixafor use was
highly associated with>2x106 /kg on ﬁrst collection (p¼.03),
but not with the total number of collections or the ability to
achieve a total yield of >5x106 /kg CD34+ cells. However,
whether or not pts got plerixafor on day 4 vs. later was
signiﬁcantly associated with sufﬁcient total CD34+ cell yield
(37% vs. 10%; p¼.016).
Conclusions: Pts who received planned plerixafor on day 4
were more likely to achieve the target yield despite having
risk factors for mobilization failure. Routine use of plerixafor
in lymphoma pts who are less likely to be poor mobilizers
may lead to fewer apheresis procedures, faster engraftment,
and shorter hospital stays. The potential economic beneﬁts of
this strategy warrant further investigation.Table 1
Data Summary
Variables Group A, N¼16 Group B, N¼16
Age* (yrs) 58 (39-72) 58 (49-68)
KPS* (%) 70 (60-80) 70 (60-80)
Creatinine Clearance
pre 2nd ASCT* (ml/min)
76 (42-129) 108 (44-218)
CR pre- 2nd ASCT [n (%)] 2 (12) 3 (14)
CD34+ cells infused for 2nd
ASCT* (x 106 cells/kg)
3.35 (2.2-10.7) 3.12 (2.79-12.04)
Febrile Neutropenia [n (%)] 10 (63) 16 (100)
In-patient stay for
2nd ASCT* (days)
15 (12-24) 23 (19-51)
CR at Day +100 post
2nd ASCT [n (%)]
2{ (14) 7x (47)
KPS- Karnofsky’s Performance score
CR- Complete response
ASCT- Autologous Stem cell transplant
* Values are median with range in parenthesis
{Day +100 response data not available for 2 patients in Group A
x Day +100 response data not available for 1 patient in Group B141
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Objetives: G-CSF has shown to shorten time to neutrophil
engraftment in autologous peripheral blood hematopoietic
stem cell transplantation (Auto-HSCT). Two ﬁlgrastim phar-
macological presentations exist for clinical use, non-pegy-
lated and pegylated. Our aim was to compare clinical
outcomes in using as support Peg-Filgrastim (PEG-F)or Fil-
grastim (F) in a group of adults undergoing autologous HSCT.
Methods: From 2010 to 2012, 69 adult patients underwent
Auto-HSTC in our BMT unit. Attending physician decided
the allocation to PEG-F or F. Other support measures
were standardized in all patients. An independent reviewer
collected data from medical records. Descriptive analyses
were carried-out as well as Kaplan-Meier survival estimates.
Results: From69 included subjects, 50 received PEG-F and 19
F. Median age was 46 vs 54 for PEG-F vs. F (P¼.05). There was
no difference by gender, body weight, diagnoses, condi-
tioning regimen, or CD34+ cells infused. Most common
diagnoses were Multiple Myeloma (48%) and Hodgkin lym-
phoma (28%). In concordance with diagnoses, Melphalan
(52%) and BEAM (46%) were the conditioning regimens most
commonly used. Median CD34+ (x106)/Kg preserved were
4.3 for PEG-F vs. 3.9 for F, (P¼.61). Median initiation of PEG-F
was 7 days after cell infusion compared to 3 days for F; P<.01.
We did not have transplant mortality death. Neutropenicfever was equal among groups (58% vs 47%). Median
number of days to achieve 500 neutrophils was 12 vs 11
(PEG-F vs F); P<.01. All patients showed neutrophil and
platelet engraftment.
Conclusions: We did not ﬁnd clinically relevant differences
among the effects of the two pharmacological ﬁlgrastim
presentations. We also found that 4 day difference in starting
the drug only represented 1 day of delay in neutrophil
engraftment without clinical repercussions. Now, we
considered changing our clinical practice by introducing
PEG-F for all patients, taking into consideration ease of
application and economical consideration.142
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Background: Salvage ASCT is increasingly utilized for
eligible MM patients (pts). High dose melphalan (HDM) is
the standard conditioning used for 1st ASCT. Despite con-
cerns for resistance, HDM is predominantly used as condi-
tioning regimen for 2nd / or salvage ASCT. BEAM (Carmustine,
etoposide, Ara-C and Melphalan) has shown superior PFS
and OS compared to HDM during 1st ASCT for MM pts. We
conducted a single institution retrospective analysis to
evaluate response and toxicity with BEAM conditioning in
2ndASCT.
Methods: Thirty two pts who received 2nd ASCT for MM
(2007-2013) were identiﬁed. Sixteen pts received HDM (140-
200mg/m2; Group A) and an equal number received BEAM
(carmustine 300 mg/m2, etoposide 100 mg/m2, cytarabine
100 mg/m2, and melphalan 140 mg/m2; Group B). Patient
characteristics, toxicity and response at day 100 were
collected and compared between the 2 groups. Fischer’s
